Shenzhen Glory Medical Co., Ltd. Class A

Shenzhen Glory Medical Co., Ltd. Class A

SSZSE:002551
3.14
CNY
+0.01
(+0.32%)
-0.17EPS
2.26BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.1
1.83
2.52
2.9
3.02
2.45
2.17
2.84
2.16
1.51
1.41
1.95
1.31
1.34
Basic EPS, GAAP
0.11
0.16
0.18
0.17
0.26
0.15
0.08
0.2
0.05
-0.36
-0.18
0.03
-0.17
-0.17
Free Cash Flow per Basic Share
-0.25
-0.14
0.2
0.21
-0.15
-0.47
-0.16
0.3
-0.23
0.05
-0.03
0.05
0.02
- -
Dividend per Share
0.06
0.05
0.08
0.03
0.05
0.13
0.11
0.06
0.04
0.19
0.07
0.01
0.03
0.02
Book Value per Share
1.93
2.02
2.19
2.65
3.19
3.29
3.34
3.72
3.76
3.26
3.09
3.12
2.94
2.9
Tangible Book Value per Share
1.83
1.78
1.7
2.05
2.63
2.74
2.8
3.37
3.04
2.65
2.76
2.77
2.63
2.6
Basic Weighted Avg Shares
664
639
662
671
665
666
706
798
831
845
845
743
821
848
Sales/Revenue/Turnover
731
1,167
1,666
1,946
2,006
1,630
1,531
2,267
1,790
1,276
1,193
1,448
1,077
1,138
Operating Margin (%)
13.03
13.2
11.88
11.81
12.2
12.55
8.27
16.9
4.48
-0.51
-1.67
3.6
-7.59
-4.56
Depreciation Expense
13
24
28
30
30
32
40
55
77
125
96
102
101
- -
Net Income, GAAP
74
102
119
114
175
98
60
162
45
-308
-149
22
-140
-142
Effective Tax Rate (%)
19.09
16.78
16.76
15.93
16.04
11.93
- -
- -
1.39
- -
- -
22.89
- -
- -
Profit Margin (%)
10.09
8.76
7.14
5.87
8.73
5.99
3.9
7.15
2.49
-24.15
-12.48
1.54
-12.96
-12.46
Working Capital
835
801
854
798
912
805
1,481
1,573
1,316
1,146
993
923
862
865
LT Debt
6
32
61
85
43
36
829
301
331
291
270
45
2
2
Total Equity
1,335
1,410
1,581
2,171
2,673
2,778
2,816
3,645
3,432
2,999
2,748
2,776
2,616
2,589
Return on Invested Capital (%)
5.45
7.48
8.24
6.08
7.21
3.79
- -
- -
1.92
- -
- -
0.96
- -
- -
Return on Capital (%)
5.7
6.92
6.22
4.95
6.38
2.42
- -
- -
0.58
- -
- -
0.76
- -
- -
Return on Common Equity (%)
5.99
7.96
8.67
7.15
8.72
4.27
2.55
5.99
1.43
-10.39
-5.54
0.85
-5.45
-5.56

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
38
48
39
LT Borrowings
2
2
2
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
845
845
845
Market Capitalization
3,086
3,052
2,257

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,488
1,417
1,417
Cash, Cash Equivalents & STI
764
754
718
Accounts Receivable, Net
387
351
392
Inventories
195
185
178
Total Current Liabilities
627
550
552
Payables & Accruals
- -
- -
- -
ST Debt
38
48
39
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.36%
-6.32%
-5.77%
Free Cash Flow
-111.66%
-156.08%
-61.33%
Net Income, GAAP
-161.99%
-351.5%
-726.43%
Sales/Revenue/Turnover
-1.73%
-12.1%
-25.61%
Total Cash Common Dividend
48.42%
71.89%
102.68%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
276
355
371
446
1,448
2025
280
248
- -
324
1,077
2026
257
308
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
0.01
0.03
2025
0.02
-0.03
- -
-0.12
-0.17
2026
- -
-0.02
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.01
2025
- -
- -
- -
0.02
0.03
2026
- -
- -
- -
- -
- -

Company Description

CEO
Gui Qiu Liang
Full Time Employees
1,322
Sector
Industrial services
Industry
Engineering & construction
Address
Building 1 Shenzhen GD China 518116
IPO Date
Feb 25, 2011
Business
Shenzhen Glory Medical Co.,Ltd. is a China-based company specializing in hospital construction and integrated medical system solutions. Founded in 1998 and headquartered in Shenzhen, China, the company operates through three main business segments: Medical Products, Medical Services, and the Health Industry. Its core product portfolio includes medical equipment and consumables such as infusion sets, syringes, rubber gloves, gauze pieces, disposable protective clothing, medical masks, X-ray machines, patient monitors, hospital beds, infusion pumps, ultrasound machines, anesthesia machines, ventilators, ECG machines, and various hospital accessories. The company also provides a range of advanced medical information technology solutions including digital operating rooms, surgical teaching systems, remote surgical consultation platforms, mobile digital video stations, and hospital central management platforms. In addition to product manufacturing and sales, Shenzhen Glory Medical offers hospital construction planning, design, management, implementation services, as well as hospital logistics and consulting services. It is also involved in health industry park investments, business incubations, and healthcare enterprise cultivation. Recently, Shenzhen Glory Medical Co.,Ltd. has focused on expanding its integrated hospital construction and digital medical solutions, promoting hospital modernization and comprehensive hospital system integration. The company completed an equity buyback in March 2024, indicating strategic financial management to enhance shareholder value. It continues to invest in technological innovation and quality improvement in hospital equipment and digital healthcare systems. The firm has maintained its operational commitment to high standards of quality and service as it broadens its geographic reach beyond China to international markets. Its owned science and technology industrial park in Shenzhen supports research and development with facilities for over 4,000 employees, underlining a strong commitment to innovation and high production capacity. Shenzhen Glory Medical serves a diverse customer base including hospitals, healthcare institutions, and government healthcare projects primarily within China and increasingly internationally. The company’s integrated solutions cover hospital construction from initial planning and design to equipment installation and ongoing hospital management services, complemented by extensive medical device manufacturing. It is publicly listed on the Shenzhen Stock Exchange since 2011 (Ticker: 002551.SZ), underlining its established position within the healthcare sector in China and signaling ongoing growth and corporate development in digital and infrastructure healthcare solutions. The company continues to leverage its technology and expanded product lines to meet evolving hospital modernization needs and enhance efficiency in healthcare delivery systems.